Literature DB >> 18246698

Primary cutaneous Cryptococcosis during therapy with methotrexate and adalimumab.

Morgan L Wilson1, Lindsay D Sewell, Christen M Mowad.   

Abstract

Primary cutaneous infection with Cryptococcus neoformans is uncommon, but can occur following an inoculation injury to the skin. Tumor necrosis factor-alpha (TNF-alpha) is important in the immune response to Cryptococcus, and patients taking inhibitors of TNF-alpha may have increased susceptibility to cryptococcal infection. We report a case of primary cutaneous cryptococcosis in a patient taking adalimumab, methotrexate, and hydroxychloroquine for rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18246698

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  4 in total

1.  Surgical Management of Primary Cutaneous Cryptococcosis after Failed Medical Management.

Authors:  Justin Leigh McKinney; Dean Cerio; Cyrus Loghmanee; Paulo Pinho; Rui Gomes; Mili Patel; Janeen Miraglia; Manal Youssef-Bessler; Jonathan Zippin; Harini Rao
Journal:  J Hand Microsurg       Date:  2014-01-28

Review 2.  The immunopathogenesis of cryptococcal immune reconstitution inflammatory syndrome: understanding a conundrum.

Authors:  David B Meya; Yukari C Manabe; David R Boulware; Edward N Janoff
Journal:  Curr Opin Infect Dis       Date:  2016-02       Impact factor: 4.915

Review 3.  Role of dendritic cell-pathogen interactions in the immune response to pulmonary cryptococcal infection.

Authors:  Alison J Eastman; John J Osterholzer; Michal A Olszewski
Journal:  Future Microbiol       Date:  2015       Impact factor: 3.165

4.  Monocyte Phenotype and IFN-γ-Inducible Cytokine Responses Are Associated with Cryptococcal Immune Reconstitution Inflammatory Syndrome.

Authors:  David B Meya; Samuel Okurut; Godfrey Zziwa; Stephen Cose; Paul R Bohjanen; Harriet Mayanja-Kizza; Moses Joloba; David R Boulware; Carol Yukari Manabe; Sharon Wahl; Edward N Janoff
Journal:  J Fungi (Basel)       Date:  2017-06-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.